跳至主要内容
临床试验/DRKS00003135
DRKS00003135已完成不适用

on-interventional study on the Management of Advanced Prostate Cancer with Triptorelin Pamoate Three Month Formulation (Pamorelin® LA 11.25 mg) or Six Month Formulation (Pamorelin® LA 22.5 mg) with a Focus on Quality of Life, using the PORPUS Questionnaire (Patient-orientated prostate utility scale) - IQUOPAM

Ipsen Pharma GmbH0 个研究点目标入组 660 人开始时间: 2011年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
660

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
Male

入选标准

  • Eligible subjects should fulfill the following:
  • Provision of written informed consent
  • Male subjects aged 18 years and older with capacity to consent
  • Histological proven prostate cancer, locally advanced or metastatic and scheduled to receive hormonal deprivation therapy or already receiving hormonal deprivation therapy (in this case, the preceding therapy and the reason for change of therapy have to be documented)
  • Definition of locally advanced: T3 or T4 or N1 with any T, M0
  • Definition of metastatic: any T, any N, M1

排除标准

  • As this is a non-interventional study, no exclusion criteria apply. The investigator has to follow the information in the SmPC, e.g. contraindications, restrictions, precautions.

研究者

相似试验

on-interventional study on the Management of... | 临床试验